甲真菌病治疗现状

摘要/Abstract

摘要： 甲真菌病是较常见的甲疾病,致病菌有皮肤癣菌、酵母菌和非皮肤癣菌性丝状真菌。常用治疗方法包括局部外用药治疗、系统口服药治疗,近来新型口服抗真菌药的研发以及局部治疗新技术的应用都将成为甲真菌病治疗的补充以及新的发展方向。该文就近年来甲真菌病的治疗现状进行综述。

关键词: 甲真菌病, 治疗, 激光疗法

Abstract: Onychomycosis is the most common nail disease. The pathogens of onychomycosis include dermatophytes, yeasts of Candida species and nondermatophyte moulds. Common treatment of onychomycosis can be divided into topical and systemic therapy. Recently, new developed antifungal agents and new technologies of topical treatment will become potent complement and new direction of onychomycosis therapy. In this article, we review the current therapeutic strategies of onychomycosis in recent years.

Key words: onychomycosis, treatment, laser treatment

中图分类号:

R 756.4

陈丽华, 朱红梅, 温海. 甲真菌病治疗现状[J]. 中国真菌学杂志, 2012, 7(3): 188-192.

CHEN Li-hua, ZHU Hong-mei, WEN Hai. Current treatment of onychomycosis[J]. Chinese Journal of Mycology, 2012, 7(3): 188-192.

参考文献

[1] Burzykowski T, Molenberghs G, Abeck D, et al. High prevalence of foot diseases in Europe: results of the Achilles project[J]. Mycoses,2003,46(11-12):496-505.
[2] Ghannoum M, Hajjeh R, Scher R, et al. A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns[J]. J Am Acad Dermatol,2000,43(4): 641-648.
[3] Gupta AK, Schouten JR, Lynch LE. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: A Canadian perspective[J].Skin Therapy Lett,2005,10(7):1-3.
[4] Lecha M, Effendy I, Feuilhade de Chauvin M, et al. Treatment options-development of consensus guidelines[J]. J Eur Acad Dermatol Venereol,2005,19(Suppl 1):25-33.
[5] Sidou F, Soto P. A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers[J]. Int J Tissue React, 2004,26(1-2 ):17-24.
[6] Baran R, Tosti A, Hartmane I, et al. An innovative water-soluble biopolymer improves efficacy of ciclopirox nail lacquer in the management of onychomycosis[J]. J Eur Acad Dermatol Venereol ,2009,23(7):773-781.
[7] Hui X, Baker SJ, Wester RC, et al.In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate[J]. J Pharm Sci, 2007,96(10):2622-2631.
[8] Bueno JG, Martinez C, Zapata B, et al.In vitro activity of fluconazole, itraconazole,voriconazole,and terbinafine against fungi causing onychomycosis[J].Clin Exp Dermatol,2010,35(6):658-663.
[9] Ataides FS, Chaul MH, El Essal FE, et al. Antifungal susceptibility patterns of yeasts and filamentous fungi isolated from nail infection[J]. J Eur Acad Dermatol Venereol, 2011,3.
[10] Tosti A, Piraccini BM, Iorizzo M. Management of onychomycosis in children[J]. Dermatol Clin, 2003, 21(3): 507-509.
[11] Sigurgeirsson, Billstei, Rantanen, et al. L.I.ON. Study: Efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis[J]. Br J Dermatol, 1999,141 (Suppl 56):5-14.
[12] Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis[J]. Br J Dermatol ,2004,150(3):537-544.
[13] 虞瑞尧, 王瑞礼.甲真菌病治疗指南[J].皮肤病与性病,2005,27(4):11-14.
[14] Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients[J]. Arch Dermatol,1997, 133(10): 1213-1219.
[15] Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality[J]. Ther Clin Risk Manag, 2005, 1(4): 299-306.
[16] Havu V, Brandt H, Heikkilä H, et al. A double-blind, randomized study comparing itraconazole pulse therapy with continuous dosing for the treatment of toe-nail onychomycosis[J]. Br J Dermatol, 1997,136(2):230-234.
[17] Chang CH, Young-Xu Y, Kurth T, et al. The safety of oral antifungal treatments for superficial dermatophytosis and onychomyco-sis: a meta-analysis[J]. Am J Med, 2007,120(9):791-798.
[18] Brown SJ. Efficacy of fluconazole for the treatment of onychomycosis[J]. Ann Pharmacother, 2009,43(10): 1684-1691.
[19] Zisova LG. Fluconazole (Fungolon) in the treatment of onychomycosis[J]. Folia Med (Plovdiv), 2004,46(3):47-50.
[20] Carrillo-Munoz AJ, Giusiano G, Guarro J, et al.In vitro activity of voriconazole against dermatophytes,Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis[J]. Int J Antimicrob Agents, 2007, 30(2):157-161.
[21] Gupta AK, Leonardi C, Stoltz RR, et al. A phase I/II randomized, double-blind, placebo-controlled,dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis[J].J Eur Acad Dermatol Venereol, 2005, 19(4):437-443.
[22] Elewski B, Pollak R, Ashton S, et al. A randomized, placebo- and active-controlled,parallel-group, multicentre, investigator-blinded study of four treatment regimens of posaconazole in adults with toenail onychomycosis[J]. Br J Dermatol, 2012,166(2):389-198.
[23] Amichai B, Nitzan B, Mosckovitz R, et al. Iontophoretic delivery of terbinafine in onychomycosis: A preliminary study[J]. Br J Dermatol, 2010, 162(1):46-50.
[24] Watanabe D, Kawamura C, Masuda Y, et al. Successful treatment of toenail onychomycosis with photodynamic therapy[J]. Arch Dermatol, 2008, 144(1):19-21.
[25] Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial[J]. Acta Derm Venereol, 2010, 90(2):216-217.
[26] Qiao J, Li R, Ding Y, et al. Photodynamic Therapy in the Treatment of Superficial Mycoses:AnEvidencebased Evaluation[J].Mycopathologia,2010,170(5):339-343.
[27] Vural E, Winfield HL, Shingleton AW, et al. The effects of laser irradiation on Trichophyton rubrum growth[J].Lasers Med Sci, 2008, 23(4): 349-353.
[28] Meral G, Tasar F, Kocagoz S, et. al. Factor affecting the antibacterial effects of NdYAG laser in vivo[J]. Lasers in Surg Med, 2003, 32(3):197-202.
[29] Landsman AS, Robbins AH, Angelini PF, et al. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure[J]. J Am Podiatr Med Assoc, 2010, 100(3):166-177.
[30] Hochman LG. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd:YAG 1064-nm laser[J]. J Cosmet Laser Ther, 2011,13(1):2-5.
[31] Manevitch Z, Lev D, Hochberg M, et al. Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis[J]. Photochem Photobiol, 2010,86(2):476-479.